New names for Bonebridge positioning.

Avoid “retrosigmoid” and “middle fossa”.

Names include easy to remember acronyms of anatomic location.

STELLA, PIA & MARA.

Identified 26 key NRGs in NPC tumors.

TMEM71 linked to immune cell infiltration in NPC.

TMEM71 as a prognostic factor in NPC.

TMEM71 inhibits NPC malignant behavior via NLRP3/caspase-1/GSDMD pathway.

Hearing loss impacts communication and mental health across ages.

Stigma and aesthetics limit hearing aid use, notably among youth.

Untreated hearing loss causes isolation and depression.

Smaller, discreet hearing aids enhance user satisfaction.

Research should diversify to explore adoption factors fully.

Large mastoid cavity after CWD mastoidectomy should be obliterated properly.

HA particles used for cavity obliteration should be properly covered.

CGF promotes complete epithelialization of the mastoid cavity.

Cuproptosis was the most enriched type of Programmed Cell Death (PCD) processes in THCA.

Cuproptosis was associated with tumor malignancy of THCA.

A cuproptosis-related gene, CDKN2A, was upregulated in THCA sample.

CDKN2A was associated with poor prognosis and TME in THCA.

RS provides unique spectral characteristics.

RS diagnosis can be completed in a short time.

Non-invasiveness, accuracy, rapidity, objectivity and cost-effectiveness.

RS not cause any damage to tumour specimens, more objective and rapid.

Facilitate the cochlear implant programming for both patients and professionals.

New possibility of evaluation in tests of pure tone and speech recognition.

Possibility of expanding the use of new evaluation methodologies.

Improve the viability of clinical care.

Expand this care model in centers that do not have a sound booth.

Otosclerosis is linked to a high rate of Sensorineural Hearing Loss (SNHL).

The prevalence of SNHL we found is higher than earlier reported.

Many otosclerosis cases with sensorineural loss may go undiagnosed, hindering care.

Our study offers insights to support further research in diagnosis and treatment.

Induction therapy with TPF or TP has been indicated for advanced HNSCC patients.

TPF is more toxic and requires infusion device or in-hospital administration of 5-FU.

We analyzed the outcomes of advanced HNSCC patients treated with TPF or TP.

ICT regimens did not alter patients’ toxicity, response rate and survival.

TP is a good treatment option for advanced HNSCC in socioeconomically limited settings.

A CI improves speech understanding and subjective hearing results within the first 12-months.

Outcomes were not dependant on age at implantation.

Cochlear implants should be offered to all eligible patients.

Use of septal bone graft intraoperatively to correct anterior septal deviations.

Reduction in the Nose Scale in patients who utilized Bone Septal Batten.

The septal bone graft usually discarded in surgery can be used in rhinoseptoplasty.

Bone grafting has low resorption rates and complications related to its use.

ALKBH5 and YTHDC1 are potential useful diagnostic markers for cochlear aging.

ALKBH5 and YTHDC1 are highly associated with immune pathways.

ALKBH5 and YTHDC1 are highly associated with immune cell infiltrate.

Use of cochlear implants can attenuate cognitive decline in adults with hearing loss.

The cognitive test should be adapted for individuals with hearing loss.

Evoked response potentials might serve as an objective marker for cognition.

External ear malformations frequently lead to conductive hearing loss.

The Jahrsdoerfer score is used to qualify patients for corrective surgery.

Patients presented improvement of bone and air-conduction thresholds.

Cochlear implantation is a solution for some patients with vestibular schwannoma.

Audiological outcomes are variable, but worse than conventional CI candidates.

Cochlear implantation can be performed in operated, observed or irradiated cases.

The Auditory Nerve Test System is a useful intraoperative tool.

A positive wave V elicited with the ANTS strongly predicts at least sound detection.

BVVL Syndrome is a rare alteration in the Riboflavin transporter gene.

Few studies describe the details of hearing loss in the syndrome.

The main finding was sensorineural hearing loss.

Objective tests were integrated into the audiological diagnosis process.

Simultaneously use disease specific and generic QoL tools in VS patients.

Use the SF-36 as a generic tool and PANQOL as a disease-specific tool in VS studies.

Including medical data, questionnaires scores referring to VS to assess HRQOL.